XHKG6622
Market cap87mUSD
Dec 30, Last price
1.24HKD
1D
-3.13%
1Q
-19.48%
IPO
-90.08%
Name
Zhaoke Ophthalmology Ltd
Chart & Performance
P/E
—
P/S
33.94
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
27.73%
Rev. gr., 5y
%
Revenues
19m
Net income
-385m
L-6.19%
CFO
-324m
L-2.23%
Profile
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 18,750 | |||||
Cost of revenue | 380,713 | 344,520 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (361,963) | (344,520) | ||||
NOPBT Margin | ||||||
Operating Taxes | 550 | 3,142 | ||||
Tax Rate | ||||||
NOPAT | (362,513) | (347,662) | ||||
Net income | (385,038) -6.19% | (410,459) -80.77% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 1,853 | 1,250 | ||||
BB yield | -0.09% | -0.08% | ||||
| Debt | ||||||
Debt current | 216,162 | 104,225 | ||||
Long-term debt | 53,313 | 65,131 | ||||
Deferred revenue | 13,705 | 7 | ||||
Other long-term liabilities | 7 | |||||
Net debt | (1,192,148) | (1,555,868) | ||||
| Cash flow | ||||||
Cash from operating activities | (323,664) | (331,050) | ||||
CAPEX | (36,467) | (238,552) | ||||
Cash from investing activities | (75,768) | (324,568) | ||||
Cash from financing activities | 99,294 | 76,230 | ||||
FCF | (389,617) | (533,993) | ||||
| Balance | ||||||
Cash | 1,461,623 | 1,725,224 | ||||
Long term investments | ||||||
Excess cash | 1,460,686 | 1,725,224 | ||||
Stockholders' equity | (3,806,856) | (3,079,138) | ||||
Invested Capital | 6,106,905 | 5,558,250 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 543,923 | 542,173 | ||||
Price | 3.95 30.79% | 3.02 -46.83% | ||||
Market cap | 2,148,495 31.22% | 1,637,362 -30.10% | ||||
EV | 956,347 | 81,494 | ||||
EBITDA | (313,259) | (309,446) | ||||
EV/EBITDA | ||||||
Interest | 7,921 | 3,142 | ||||
Interest/NOPBT | ||||||